NCT00538902 - Safety and Efficacy Study of Adalimumab in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate | Biotech Hunter

Enrollment

302

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

December 31, 2009

Conditions

Rheumatoid Arthritis

Interventions

BIOLOGICAL

Placebo

Placebo administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.

BIOLOGICAL

Adalimumab 80 mg

Adalimumab 80 mg administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.

BIOLOGICAL

Adalimumab 40 mg

Adalimumab 40 mg administered subcutaneously every other week for 104 weeks

Trial Locations (11)

Site Reference ID/Investigator# 6248, Hepingjiebeikou

Site Reference ID/Investigator# 6266, Beijing

Site Reference ID/Investigator# 6241, Beijing

Site Reference ID/Investigator# 6262, Harbin

Site Reference ID/Investigator# 6250, Shanghai

Site Reference ID/Investigator# 6828, Shanghai

Site Reference ID/Investigator# 6333, Shanghai

Site Reference ID/Investigator# 6259, Hefei

Site Reference ID/Investigator# 6243, Guangzhou

Site Reference ID/Investigator# 6247, Guangzhou

Site Reference ID/Investigator# 6264, Xi'an